Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688076'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 20.42 Med: 37.53 Max: 96.74
Current: 32.23
During the past 10 years, the highest EV-to-EBITDA of Sinopep Allsino Bio Pharmaceutical Co was 96.74. The lowest was 20.42. And the median was 37.53.
SHSE:688076's EV-to-EBITDA is ranked worse than 73.27% of 404
companies
in the Biotechnology industry
Industry Median: 13.03
vs SHSE:688076: 32.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinopep Allsino Bio Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sinopep Allsino Bio Pharmaceutical Co's share price for today is ¥28.54.
Sinopep Allsino Bio Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co EV-to-EBITDA Chart
SHSE:688076 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sinopep Allsino Bio Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopep Allsino Bio Pharmaceutical Co EV-to-EBITDA vs Biotechnology Industry
Sinopep Allsino Bio Pharmaceutical Co's current Enterprise Value is ¥10,928 Mil.
Sinopep Allsino Bio Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥339 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a EV-to-EBITDA of 32.23 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinopep Allsino Bio Pharmaceutical Co. This is 14% below median its historical median of 37.53. Over the past decade, Sinopep Allsino Bio Pharmaceutical Co's EV-to-EBITDA has ranged from 20.42 to 96.74. According to the industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #296 out of 404 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Sinopep Allsino Bio Pharmaceutical Co's EV-to-EBITDA too high?
Sinopep Allsino Bio Pharmaceutical Co's current EV-to-EBITDA of 32.23 is 14% below median its 10-year median of 37.53. Over the past 10 years, this metric has ranged from a low of 20.42 to a high of 96.74. The Biotechnology industry median EV-to-EBITDA is 13.03. Sinopep Allsino Bio Pharmaceutical Co's value of 32.23 is 147.4% above this industry median. Based on the distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #296 out of 404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinopep Allsino Bio Pharmaceutical Co ranks #296 out of 404 companies for EV-to-EBITDA. This places Sinopep Allsino Bio Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. Sinopep Allsino Bio Pharmaceutical Co's value of 32.23 is 147.4% above this benchmark. Historically, Sinopep Allsino Bio Pharmaceutical Co's own EV-to-EBITDA has ranged from 20.42 to 96.74 over the past decade. While the company's 10-year median is 37.53 vs. the industry median of 13.03, Sinopep Allsino Bio Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.03, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopep Allsino Bio Pharmaceutical Co's current EV-to-EBITDA of 32.23 is 147.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinopep Allsino Bio Pharmaceutical Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopep Allsino Bio Pharmaceutical Co's current EV-to-EBITDA is 32.23, which is 14% below median its own 10-year median of 37.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥56.31, compared to a current price of ¥28.54 — trading 49.3% below its estimated fair value. The current EV-to-EBITDA is 32.23, which is 14% below median its 10-year median of 37.53 and 147.4% above the Biotechnology industry median of 13.03. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current EV-to-EBITDA is 32.23 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥28.54 is trading 49.3% below its estimated GF Value™ of ¥56.31.
GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:688076:
EV-to-EBITDA: 32.23 (14% below median its 10-year median of 37.53)
GF Value™: ¥56.31 vs. price of ¥28.54 (49.3% below fair value)
Industry Position: 147.4% above the Biotechnology median (#296 of 404)
No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
74GF Score
Get the complete analysis for SHSE:688076
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688076 has been successfully added to your 
